Pyridylfuran and pyridylthiophene compounds

A compound of the formula: 1 and its pharmaceutically effective salts, wherein R 1 and R 2 are independently selected from the following: (a) hydrogen, halo, R 5 -, C 2-6 alkenyl, C 2-6 alkynyl, hydroxy-R 5 -, R 5 -O-R 5 -, or the like; (b) Ar-, Ar-R 5 -, Ar-C 2-6 alkenyl, Ar-C 2-6 alkynyl, Ar-O-, Ar-O-R 5 - or the like; (c) R 5 -C(O)-, -NO 2 , cyano, NH 2 -C(O)-, R 5 -NH-C(O)-, (R 5 ) 2 -N-C(O)-, Ar-C(O)- or the like; and (d) R 5 -C(O)-NH-, Ar-C(O)-NH- or the like; wherein Ar is optionally substituted aryl or heteroaryl such as phenyl and pyridyl; and wherein R 5 is optionally halo-substituted C 1-6 alkyl; R 3 is selected from the following: (e) cyano, formyl, tetrazolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, R 5 -C(O)-, C 2-6 alkenyl-C(O)-, C 2-6 alkynyl-C(O)-, R 5 -C(O)-R 5 -, or the like; (f) R 5 -C(O)-NH-, Ar-C(O)-NH-, or the like; (g) R 5 -S-, R 5 -S(O)-, R 5 -NH-S(O) 2 -, or the like; and (h) Ar-C(O)-, Ar-R 5 -C(O)-, Ar-C 2-6 alkenylene-C(O)- or the like; or two of R 1 , R 2 and R 3 together form a group of the formula -A 1 -B 1 -A 2 - or -A 1 -B 1 -A 3 -B 2 -A 2 - such as cyclic alkyl optionally substitued with oxo; R 4 is hydrogen, halo, R 5 -C(O)- and the like; X is O, S, S(O) or S(O) 2 ; m is 0, 1, 2, 3 or 4. The present invention also provides processes for the preparation thereof, the use thereof in treating cytokine mediated diseases and/or cell adhesion molecule (CAM) mediated diseases and pharmaceutical compositions for use in such therapy.